论文部分内容阅读
目的研究参附注射液对慢性心力衰竭患者美托洛尔耐受性的影响。方法以失代偿期慢性心力衰竭的住院患者为研究对象,随机分为参附注射液组30例和对照组32例,通过分析美托洛尔使用剂量、心率、平均动脉血压、血肌酐、血尿素氮等变量,判断参附注射液对美托洛尔使用剂量的影响。结果参附注射液组美托洛尔使用剂量明显高于对照组,差异有统计学意义(P<0.05),而对心率、平均动脉血压、血肌酐、血尿素氮等变量无显著影响,差异无统计学意义(P>0.05)。结论对于失代偿慢性心力衰的患者,住院期间使用参附注射液可显著增加患者对美托洛尔的耐受性,有利于神经激素阻断药物的积极使用,从而改善心力衰竭患者远期预后。从而更早、更积极的启动神经激素阻断治疗。
Objective To study the effect of Shenfu Injection on metoprolol tolerance in patients with chronic heart failure. Methods In-hospital patients with decompensated chronic heart failure were randomly divided into two groups, 30 cases in the Shenfu injection group and 32 cases in the control group. Through the analysis of metoprolol dose, heart rate, mean arterial pressure, serum creatinine, Blood urea nitrogen and other variables to determine the Shenfu injection on the use of metoprolol dose. Results The dose of metoprolol in Shenfu injection group was significantly higher than that of the control group (P <0.05), while there was no significant difference in the variables such as heart rate, mean arterial pressure, serum creatinine and blood urea nitrogen No statistical significance (P> 0.05). Conclusions For patients with decompensated chronic heart failure, Shenfu injection during hospitalization can significantly increase the patient’s tolerance to metoprolol, which is beneficial to the active use of neurohormonal blocking drugs and thereby improve the long-term prognosis of patients with heart failure Prognosis. Thus, earlier, more active start hormone block therapy.